Medication info
Lorestor 5 mg (Rosuvastatin Calcium)

Lorestor 5 mg (Rosuvastatin Calcium)

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium Micronized›5.2mg / 1 tablet
Manufacturer / importer
Albott Pharmaceutical Co., Ltd.
Appearance
Yellow, round film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201400289 · Approved 2014.01.22 · Insurance code 652604150

Summary

Main use
Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The starting dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 3. Older adults: No dose adjustment is needed. 4. Patients with renal impairment: No dose adjustment is needed in patients with mild or moderate renal impairment. Do not use in patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended starting dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended starting dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Child dose
2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Children under 10 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
Albott Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used as an adjunct when dietary interventions and exercise do not adequately control primary hypercholesterolemia and mixed dyslipidemia. It is also effective as an adjunct to dietary treatment or other lipid-lowering therapies in patients with homozygous familial hypercholesterolemia. It helps to lower total cholesterol and LDL cholesterol to target levels in patients with hypercholesterolemia, thereby slowing the progression of atherosclerosis. It is also used to reduce total cholesterol and LDL cholesterol in pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia, in conjunction with dietary interventions. Additionally, it serves as an adjunct to dietary treatment in patients with primary dysbetalipoproteinemia. Finally, it aids in reducing the risk of stroke, myocardial infarction, and arterial revascularization procedures in adult patients at high risk for cardiovascular disease. It is effectively utilized for various dyslipidemias and reducing cardiovascular disease risk.

How to take

Adult dose

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The starting dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams daily. 3. Older adults: No dose adjustment is needed. 4. Patients with renal impairment: No dose adjustment is needed in patients with mild or moderate renal impairment. Do not use in patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended starting dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended starting dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Child dose

2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Children under 10 years: Safety and efficacy have not been established.

Precautions

This medication should not be used in certain patients. For example, it should not be taken by patients with allergies to any of its ingredients, those with severely impaired liver function, individuals with muscle disorders, patients with severely impaired kidney function, or women who are pregnant or nursing. Additionally, high doses of this medication are prohibited in patients at high risk for muscle damage, including those with impaired kidney function, hypothyroidism, a history of genetic muscle disorders, or alcohol abuse. This medication contains lactose, so patients with lactose intolerance should not take it. Patients with a history of liver disease or those who consume large amounts of alcohol should undergo liver function tests before and regularly during treatment with this medication. If any symptoms of muscle pain or weakness occur, patients should promptly notify their healthcare provider, and blood tests may be needed to check for muscle damage. This medication may interact with other drugs, so it is essential to inform the doctor or pharmacist of any concurrent medications. Special caution is required when taken with certain antiviral drugs, immunosuppressants, and fibrate class medications. Women who are pregnant or planning to become pregnant should not take this medication, and if pregnancy occurs during treatment, it should be discontinued immediately. In the case of overdose, there is no specific antidote; treatment should be symptomatic along with tests of liver function and muscle enzymes. This medication may cause rare but severe skin reactions or liver damage, so if symptoms like rash, jaundice, or severe fatigue occur, the medication should be stopped immediately and healthcare consultation sought. Symptoms such as dizziness or headache may occur, hence caution is advised when driving or operating machinery. When administered to children or adolescents, their growth and development should be closely monitored.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, shortness of breath, diarrhea, oculobulbar weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, fixed drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paraesthesia, chest discomfort, loss of appetite, abdominal distension, syncope, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly sealed container to prevent air or moisture. It is recommended to maintain a storage temperature between 1 degree and 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Yellow, round film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.